- Home
- SQFT vs RNAZ Comparison
SQFT vs RNAZ Comparison
Compare SQFT & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- RNAZ
- Stock Information
- Founded
- SQFT 1999
- RNAZ 2016
- Country
- SQFT United States
- RNAZ United States
- Employees
- SQFT N/A
- RNAZ N/A
- Industry
- SQFT Real Estate Investment Trusts
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- SQFT Real Estate
- RNAZ Health Care
- Exchange
- SQFT Nasdaq
- RNAZ Nasdaq
- Market Cap
- SQFT 7.7M
- RNAZ 8.7M
- IPO Year
- SQFT 2020
- RNAZ 2021
- Fundamental
- Price
- SQFT $5.63
- RNAZ $9.63
- Analyst Decision
- SQFT
- RNAZ Strong Buy
- Analyst Count
- SQFT 0
- RNAZ 1
- Target Price
- SQFT N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- SQFT 30.2K
- RNAZ 48.2K
- Earning Date
- SQFT 11-11-2025
- RNAZ 11-14-2025
- Dividend Yield
- SQFT N/A
- RNAZ N/A
- EPS Growth
- SQFT N/A
- RNAZ N/A
- EPS
- SQFT N/A
- RNAZ N/A
- Revenue
- SQFT $18,052,597.00
- RNAZ N/A
- Revenue This Year
- SQFT $23.63
- RNAZ N/A
- Revenue Next Year
- SQFT N/A
- RNAZ N/A
- P/E Ratio
- SQFT N/A
- RNAZ N/A
- Revenue Growth
- SQFT N/A
- RNAZ N/A
- 52 Week Low
- SQFT $4.19
- RNAZ $6.15
- 52 Week High
- SQFT $23.00
- RNAZ $494.25
- Technical
- Relative Strength Index (RSI)
- SQFT 44.38
- RNAZ 34.16
- Support Level
- SQFT $5.52
- RNAZ $10.90
- Resistance Level
- SQFT $6.40
- RNAZ $13.92
- Average True Range (ATR)
- SQFT 0.39
- RNAZ 0.88
- MACD
- SQFT -0.02
- RNAZ -0.54
- Stochastic Oscillator
- SQFT 23.00
- RNAZ 9.09
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.